| Bioactivity | Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19[1][2][3][4][5]. | ||||||||||||
| Invitro | Deferoxamine (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells[1].Deferoxamine (100 µM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels[2].Deferoxamine (5, 10, 25, 50, 100 µM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs[3].Deferoxamine (5, 10, 25, 50, 100 µM; 7 days) induces apoptosis of MSCs[3].Deferoxamine (10 µM ; 3 days) influencs the expression of adhesion proteins on MSCs[3].Deferoxamine (100 µM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells[4]. Western Blot Analysis[1] Cell Line: | ||||||||||||
| Name | Deferoxamine | ||||||||||||
| CAS | 70-51-9 | ||||||||||||
| Formula | C25H48N6O8 | ||||||||||||
| Molar Mass | 560.68 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|